The University of Tokyo
Medical School Hospital
Department of Surgery
Anesthesiology and Pain Relief Center
日本語
Update date：2025/02/20
Project Lecturer
ABE HIROAKI

Education

  1. 東京大学1996/03/31工学部建築学科graduated
  2. 東京大学1998/03/31工学系研究科建築学専攻master coursecompleted
  3. The University of Tokyo2005/03/31医学部医学科graduated
  4. 東京大学2018/03/31医学系研究科外科学専攻doctor coursecompleted

Degree

  1. 工学修士東京大学1998/03/31
  2. 医学博士東京大学2018/03/31

Licenses and Qualifications

  1. license2005/04
  2. qualification2015/04
  3. qualification2019/04
  4. qualification2019/04
  5. qualification2023/02

Research Projects

  1. The University of TokyoInvestigations Toward Precision Pain MedicineGrant-in-Aid for Scientific Research (B)2019/04/01-2022/03/01
  2. The University of Tokyo肥満による術後急性期疼痛の重症化機序と制御に関する研究Grant-in-Aid for Scientific Research (C)2019/04/01-2022/03/01
View details...

Papers

  1. Efficacy of treatments for pain and numbness in cancer survivors: a systematic review and meta-analysis.2022/12Abe Hiroaki,Inoue Reo,Tsuchida Rikuhei,Ando Masae,Saita Kosuke,Konishi Mitsuru,Edamura Tatsuma,Ogawa Asao,Matsuoka Yutaka,Sumitani MasahikoAnnals of palliative medicine11/ 12, 3674-369610.21037/apm-22-4202224-5839Pain and numbness in cancer survivors frequently have negative impacts on quality of life (QoL). This meta-analysis aimed to identify the current treatment options for pain and numbness in cancer survivors and to evaluate their effects.Cancer survivors were defined as patients diagnosed with cancer who had completed active cancer treatment, whose conditions were stable, and who had no evidence of recurrent or progressive disease. A systematic search through the PubMed, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Web of Science, PsycInfo, and CINAHL databases was conducted, which targeted randomized controlled trials (RCTs) published until April 2022 that evaluated any type of treatment for pain or numbness in cancer survivors. A meta-analysis was conducted using the random-effects model to obtain the effect sizes of 7 types of treatments: opioid therapy, nonopioid pharmacotherapy, interventional therapy, acupuncture, education/cognitive behavioral therapy (CBT), physical exercise, and alternative medicine.A total of 36 studies involving 2,870 cancer survivors were included. Among them, 35 (n=2,813) were included in the meta-analysis for pain. The analysis suggested that physical exercise [n=761; 13 studies; standardized mean difference (SMD) -0.84; 95% confidence interval (CI): -1.14 to -0.55], acupuncture (n=409; 3 studies; SMD -0.80; 95% CI: -1.04 to -0.56), and alternative medicine (n=206; 6 studies; SMD -0.44; 95% CI: -0.71 to -0.16) could significantly reduce pain. Nonopioid pharmacotherapy and education/CBT did not demonstrate significant effects. No studies were identified that investigated the effects of opioid therapy or interventional therapy on pain. Regarding numbness, 5 studies (n=566) were included in the meta-analysis. Acupuncture (n=99; 2 studies) did not demonstrate significant effects on numbness, and the effects of nonopioid pharmacotherapy, education/CBT, and physical exercise could not be determined due to the small number of included studies. No studies were identified that investigated the effects of opioid therapy, interventional therapy, or alternative medicine on numbness.This meta-analysis suggested that physical exercise, acupuncture, and alternative medicine may reduce pain in cancer survivors, with a very small to moderate amount of evidence. The effect of treatments for numbness could not be determined due to the limited number of included studies. Further studies are needed, particularly on widely used pharmacotherapy.
  2. Gabapentinoid Use Is Associated With Reduced Occurrence of Hyperactive Delirium in Older Cancer Patients Undergoing Chemotherapy: A Nationwide Retrospective Cohort Study in Japan.2022/08/01Abe Hiroaki,Sumitani Masahiko,Matsui Hiroki,Inoue Reo,Konishi Mitsuru,Fushimi Kiyohide,Uchida Kanji,Yasunaga HideoAnesthesia and analgesia135/ 2, 362-36910.1213/ANE.00000000000060931526-7598It is unclear whether gabapentinoids affect the development of delirium. We aimed to determine the association between gabapentinoid use and hyperactive delirium in older cancer patients undergoing chemotherapy.We conducted propensity score-matched analyses using data from a nationwide inpatient database in Japan. We included cancer patients with pain ≥70 years of age undergoing chemotherapy between April 2016 and March 2018. Patients receiving gabapentinoids were matched with control patients using propensity scores. The primary outcome was occurrence of hyperactive delirium during hospitalization, and the secondary outcomes were length of hospital stay, in-hospital fractures, and in-hospital mortality. Hyperactive delirium was identified by antipsychotic use or discharge diagnoses from the International Classification of Diseases, 10th Revision.Among 143,132 identified patients (59% men; mean age, 76.3 years), 14,174 (9.9%) received gabapentinoids and 128,958 (90.1%) did not (control group). After one-to-one propensity score matching, 14,173 patients were included in each group. The occurrence of hyperactive delirium was significantly lower (5.2% vs 8.5%; difference in percent, -3.2% [95% confidence interval, -3.8 to -2.6]; odds ratio, 0.60 [0.54-0.66]; P < .001), the median length of hospital stay was significantly shorter (6 days [interquartile range, 3-15] vs 9 days [4-17]; subdistribution hazard ratio, 1.22 [1.19-1.25]; P < .001), and the occurrence of in-hospital mortality was significantly lower in the gabapentinoid group than in the control group (1.3% vs 1.8%; difference in percent, -0.6% [-0.9 to -0.3]; odds ratio, 0.69 [0.57-0.83]; P < .001). Gabapentinoid use was not significantly associated with the occurrence of in-hospital fractures (0.2% vs 0.2%; difference in percent, 0.0% [-0.1 to 0.1]; odds ratio, 1.07 [0.65-1.76]; P = .799). The results of sensitivity analyses using stabilized inverse probability of treatment weighting were consistent with the results of the propensity score-matched analyses.Our findings suggest that gabapentinoid use is associated with reduced hyperactive delirium in older cancer patients undergoing chemotherapy, with no evidence of an increase in the fracture rate, length of hospital stay, or in-hospital death.
  3. Use of naldemedine is associated with reduced incidence of hyperactive delirium in cancer patients with opioid-induced constipation: A nationwide retrospective cohort study in Japan.2022/03Abe Hiroaki,Sumitani Masahiko,Matsui Hiroki,Inoue Reo,Fushimi Kiyohide,Uchida Kanji,Yasunaga HideoPharmacotherapy42/ 3, 241-24910.1002/phar.26581875-9114Medical benefits of peripherally acting mu-opioid receptor antagonists other than improving opioid-induced constipation remain unclear. Our aim was to evaluate the association between the use of naldemedine and incidence of hyperactive delirium in cancer patients receiving chemotherapy and opioid therapy.We conducted a propensity score-matched analysis using a nationwide inpatient database in Japan. Cancer patients receiving both inpatient chemotherapy and opioid therapy from June 1, 2017, to March 31, 2018, were included. Patients receiving naldemedine were matched to control patients by propensity score. Our primary outcome was the incidence of hyperactive delirium during hospitalization, and secondary outcomes were the length of hospital stay, hospital costs, in-hospital mortality, and incidence of ileus.Of 34,031 patients receiving inpatient chemotherapy and opioid therapy, 1905 (5.6%) were included in the naldemedine group. After one-to-four propensity score matching, 1904 patients were included in the naldemedine group and 7616 in the control group. Naldemedine users had significantly reduced incidence of hyperactive delirium compared with the control patients (19.4% vs 23.3%; risk difference, -3.9 [95% confidence interval, -5.9 to -1.9]; risk ratio, 0.83 [0.75-0.92]; p<0.001; subdistribution hazard ratio, 0.85 [0.75-0.97]; p = 0.015). The median length of hospital stay was significantly shorter in the naldemedine group compared with the control group (12 days [interquartile range, 6-23] vs 14 days [6-26]; p = 0.001). The median hospital costs were also significantly lower in the naldemedine group compared with the control group (US $6179 [3351-10,026] vs US $6576 [3436-11,107]; p < 0.001). No significant differences were found for in-hospital mortality or incidence of ileus between the groups.Our findings suggest that the use of naldemedine may have benefits in preventing hyperactive delirium, shortening hospital stay, and decreasing hospital costs in cancer patients receiving chemotherapy and opioid therapy.
  4. Use of three-dimensional printing of a lumbar skeletal model for intrathecal administration of nusinersen: a brief technical report.2020/10Abe Hiroaki,Inoue Reo,Tsuchida Rikuhei,Azuma Kenji,Ino Kenji,Konishi Mitsuru,Hozumi Jun,Sumitani MasahikoRegional anesthesia and pain medicine45/ 10, 757-76010.1136/rapm-2020-1016071532-8651Spinal muscular atrophy (SMA) is an autosomal recessive hereditary neurodegenerative disease causing progressive muscle atrophy, weakness and kyphoscoliosis. Nusinersen is a therapeutic agent for SMA that should be administered intrathecally. However, due to severe kyphoscoliosis, lumbar puncture can be challenging. Here, we present our experience of intrathecal administration of nusinersen in an SMA patient with severe kyphoscoliosis using a life-size three-dimensional printing (3D) skeletal model created with 3D printer. With this strategy, we were able to rapidly and safely perform the lumbar puncture.
  5. Comparing outcomes after peripheral nerve block versus general anesthesia for lower extremity amputation: a nationwide exploratory retrospective cohort study in Japan.2020/06Abe Hiroaki,Sumitani Masahiko,Matsui Hiroki,Aso Shotaro,Inoue Reo,Fushimi Kiyohide,Uchida Kanji,Yasunaga Hideo,Yamada YoshitsuguRegional anesthesia and pain medicine45/ 6, 399-40410.1136/rapm-2019-1012081532-8651The health benefits of peripheral nerve block (PNB) on postoperative complications after lower extremity amputation (LEA) compared with general anesthesia (GA) remains controversial. We performed a retrospective propensity score-matched cohort analysis to compare major outcomes after LEA with PNB versus GA.We used a nationwide inpatient database in Japan to compare patient outcomes after LEA with PNB versus GA from 2010 to 2016. Our primary outcome was 30-day mortality after LEA. The incidence of composite morbidity from life-threatening complications and of delirium within 30 days after LEA were secondary outcomes. We conducted propensity score-matched analyses of patients who underwent below knee or foot amputation using 36 covariates. Logistic regression analyses fitted with generalized estimating equations were performed to calculate ORs and their 95% CIs.Of 11 796 patients, 747 received PNB and 11 049 received GA. After one-to-four propensity score matching, 747 patients were included in the PNB group and 2988 in the GA group. The adjusted ORs for postoperative mortality, composite morbidity and delirium within 30 days after LEA were 1.11 (95% CI 0.75 to 1.64), 1.15 (95% CI 0.85 t o1.56) and 0.75 (95% CI 0.57 to 0.98), respectively, for the PNB group with reference to the GA group.There was no significant difference between groups in 30-day mortality or composite morbidity. The PNB group showed a significantly lower risk of postoperative delirium than the GA group. Our findings suggest that PNB may have advantages over GA in preventing postoperative delirium among patients undergoing LEA.
View details...

Awards

  1. 2025/06/05青洲賞麻酔・ペイン・緩和ケア領域における医療ビッグデータの利活用
  2. 2023/06/02日本麻酔科学会 第70回学術集会 優秀演題賞化学療法中のがん患者におけるクロピドグレル使用とオピオイド使用量の関連：DPCデータを用いた nationwide retrospective cohort study
  3. 2022/07/01第27回 日本緩和医療学会学術大会 優秀演題がんサバイバーにおける痛み・しびれに対する治療とその効果:システマティックレビュー&メタアナリシス
  4. 2021/06/19第26回 日本緩和医療学会学術大会 優秀演題ナルデメジンは化学療法中のがん患者のせん妄発症を抑制し、入院期間を短縮、入院コストを低減させる可能性がある -DPC データベースを用いた傾向スコア分析-
  5. 2021/01/15人日本ペインクリニック学会 第54回学術集会 最優秀演題賞下肢切断術後の幻肢痛・難治性疼痛の発症と麻酔法との関連 －DPCデータベースを用いた観察研究－
View details...